Smithfield Trust’s GSK GSK Stock Holding History

Smithfield Trust’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$95K	Hold	1,709	–	–	﹤0.01%	492
2025 Q4	$84K	Buy	1,709 +114	+7%	+$5.32K	﹤0.01%	507
2025 Q3	$69K	Hold	1,595	–	–	﹤0.01%	524
2025 Q2	$61K	Sell	1,595 -400	-20%	-$15.3K	﹤0.01%	532
2025 Q1	$76K	Hold	1,995	–	–	﹤0.01%	477
2024 Q4	$68K	Sell	1,995 -3,558	-64%	-$128K	﹤0.01%	513
2024 Q3	$228K	Sell	5,553 -192	-3%	-$7.86K	0.01%	327
2024 Q2	$219K	Hold	5,745	–	–	0.01%	310
2024 Q1	$245K	Hold	5,745	–	–	0.01%	295
2023 Q4	$212K	Sell	5,745 -371	-6%	-$13.3K	0.01%	304
2023 Q3	$221K	Buy	6,116 +451	+8%	+$16K	0.01%	282
2023 Q2	$202K	Hold	5,665	–	–	0.01%	307
2023 Q1	$200K	Buy	+5,665	New	+$198K	0.01%	297
2022 Q3	–	Sell	-3,299	Closed	-$180K	–	1067
2022 Q2	$180K	Hold	3,299	–	–	0.01%	303
2022 Q1	$180K	Hold	3,299	–	–	0.01%	326
2021 Q4	$182K	Buy	3,299 +1,192	+57%	+$62K	0.01%	339
2021 Q3	$101K	Hold	2,107	–	–	0.01%	436
2021 Q2	$104K	Hold	2,107	–	–	0.01%	432
2021 Q1	$94K	Hold	2,107	–	–	0.01%	450
2020 Q4	$97K	Sell	2,107 -442	-17%	-$20.3K	0.01%	430
2020 Q3	$120K	Hold	2,549	–	–	0.01%	371
2020 Q2	$130K	Hold	2,549	–	–	0.01%	342
2020 Q1	$121K	Buy	2,549 +808	+46%	+$43.1K	0.01%	308
2019 Q4	$102K	Buy	1,741 +32	+2%	+$1.78K	0.01%	395
2019 Q3	$92K	Hold	1,709	–	–	0.01%	408
2019 Q2	$86K	Hold	1,709	–	–	0.01%	432
2019 Q1	$89K	Hold	1,709	–	–	0.01%	411
2018 Q4	$82K	Hold	1,709	–	–	0.01%	395
2018 Q3	$86K	Hold	1,709	–	–	0.01%	434
2018 Q2	$86K	Hold	1,709	–	–	0.01%	435
2018 Q1	$83K	Sell	1,709 -780	-31%	-$36.3K	0.01%	429
2017 Q4	$110K	Buy	2,489 +576	+30%	+$26.6K	0.01%	396
2017 Q3	$97K	Hold	1,913	–	–	0.01%	401
2017 Q2	$103K	Hold	1,913	–	–	0.02%	405
2017 Q1	$100K	Sell	1,913 -31	-2%	-$1.57K	0.02%	402
2016 Q4	$94K	Hold	1,944	–	–	0.02%	411
2016 Q3	$105K	Buy	1,944 +128	+7%	+$7.02K	0.02%	378
2016 Q2	$98K	Hold	1,816	–	–	0.02%	386
2016 Q1	$92K	Hold	1,816	–	–	0.02%	394
2015 Q4	$92K	Sell	1,816 -480	-21%	-$24.5K	0.02%	391
2015 Q3	$110K	Buy	2,296 +466	+25%	+$24.3K	0.02%	358
2015 Q2	$95K	Hold	1,830	–	–	0.02%	394
2015 Q1	$106K	Buy	1,830 +265	+17%	+$15.2K	0.02%	391
2014 Q4	$84K	Sell	1,565 -1,026	-40%	-$57.4K	0.02%	423
2014 Q3	$149K	Sell	2,591 -172	-6%	-$10.5K	0.03%	350
2014 Q2	$185K	Hold	2,763	–	–	0.04%	347
2014 Q1	$185K	Hold	2,763	–	–	0.04%	359
2013 Q4	$184K	Buy	2,763 +80	+3%	+$5.19K	0.04%	354
2013 Q3	$168K	Sell	2,683 -85	-3%	-$5.47K	0.04%	350
2013 Q2	$173K	Buy	+2,768	New	+$176K	0.04%	334

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Smithfield Trust's GSK Position: Q1 2026 in Review

Smithfield Trust held its GSK (GSK) position steady in Q1 2026 at 1,709 shares worth $95K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

Smithfield Trust first reported a position in GSK in Q2 2013 and has held it in 50 quarters since. The position peaked at $245K in Q1 2024. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Smithfield Trust held 1,709 shares of GSK worth $95K as of Q1 2026.
Smithfield Trust left its GSK share count unchanged in Q1 2026.
GSK made up ﹤0.01% of Smithfield Trust's portfolio in Q1 2026, its #492 holding.
Smithfield Trust first reported a position in GSK in Q2 2013 and has held it in 50 quarters since.
Smithfield Trust's GSK position peaked at $245K in Q1 2024.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.